Prima BioMed (PBMD) Immunotherapy Delivery Method Looks Promising - Maxim Group
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
FBR Capital Remains Bullish as Prima BioMed (PBMD) Announces Investigator-Sponsored Trial
July 12, 2016 1:47 PM EDTFBR Capital reiterated an Outperform rating and $6.00 price target on Prima Biomed (NASDAQ: PBMD) following the company's announced collaboration for an investigator-sponsored clinical trial.
Analyst Vernon Bernardino commented, "Earlier today, July 12, Prima BioMed (PBMD) announced a new collaboration for an investigatorsponsored clinical trial named INSIGHT to evaluate intra-tumoral injection of PBMDs immune-oncology therapy,... More
